In the carriers of this mutation, the β’-site cleaving activity of BACE1 (the prime target of the ACH2.0-base drugs) is significantly enhanced, yet the only effect these individuals are experiencing is beneficial: protection from both AD and aging-associated cognitive decline [25,26]. Here, BACE1 is linked to Alzheimer disease.